Pfizer has acquired Amplyx Pharmaceuticals in a deal that expands its anti-infectives pipeline.
Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.
Fosmanogepix has a novel mechanism of action with the potential to target fungal strains resistant to standard of care therapy.
As there are only three classes of antifungal medications currently available, antifungal resistance can severely limit treatment options; a potential new therapeutic class may therefore be of importance for both physicians and patients.
There has been no novel therapeutic class of antifungal therapies approved by the US Food and Drug Administration in nearly 20 years.
“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,” said Angela Lukin, Global President, Pfizer Hospital.
She added: “We’ve already invested in assets that, if approved, could help address drug-resistant bacterial infections and critical viral infections; with this acquisition, we look forward to progressing the development of a novel anti-fungal as well.”
Fosmanogepix is currently in Phase 2 clinical trials evaluating the safety and efficacy of both intravenous and oral formulations for the treatment of patients with life-threatening invasive fungal infections caused by moulds, yeasts and rare moulds.
Fosmanogepix has demonstrated broad-spectrum activity in-vitro and has shown wide distribution to various tissues including the brain, lung, kidney and eye.
With both IV and oral formulations in development, Fosmanogepix may allow for the transition from IV to oral, thus potentially enabling, for the benefit of patients, the continuation of treatment outside the hospital.
Financial terms of the acquisition were not disclosed.